Top 10 Companies in the Heparin Sodium API and Heparin Calcium API Market (2026): Market Leaders Powering Global Pharmaceutical Solutions

Market Insight

Global Heparin Sodium API and Heparin Calcium API market size was valued at USD 2.635 billion in 2023, with projections indicating substantial growth over the forecast period. By 2032, the market is expected to reach USD 7.667 billion, reflecting a robust compound annual growth rate (CAGR) of 12.60%.

This growth is fueled by rising demand for anticoagulant drugs and the increasing use of heparin products in treating cardiovascular diseases, as well as in the prevention of blood clots during surgeries. The market growth is also supported by advancements in heparin production and its applications in various therapeutic areas.

Heparin is a naturally occurring anticoagulant that prevents blood clotting. It is widely used in clinical settings to treat and prevent thrombosis (blood clotting) in veins, arteries, or the lungs. Heparin is commonly available in two main forms—Heparin Sodium and Heparin Calcium. These products are primarily used in hospitals for patients undergoing surgeries, dialysis, or for those suffering from blood clot-related conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE).

Heparin Sodium and Heparin Calcium are both critical active pharmaceutical ingredients (APIs) in the global pharmaceutical industry. The primary differences between Heparin Sodium and Heparin Calcium lie in their chemical composition, yet both serve the same fundamental purpose in medical treatments. The growth of this market is intricately linked to the demand for injectable drugs, especially in cardiovascular diseases and surgical procedures.

Heparin Sodium API and Heparin Calcium API Market – View in Detailed Research Report

Top 10 Companies in the Heparin Sodium API and Heparin Calcium API Market

---

10️⃣ 1. Shenzhen Hepalink Pharmaceutical

Headquarters: Shenzhen, China
Key Offering: Heparin Sodium API, Heparin Calcium API, and related pharmaceutical intermediates

Shenzhen Hepalink has established itself as a leading manufacturer of heparin APIs, focusing on high purity and consistent supply for global pharmaceutical clients. The company invests heavily in GMP-compliant facilities and advanced extraction technologies to meet stringent regulatory requirements.

Sustainability & Growth Initiatives:

• Implementation of animal welfare compliant sourcing programs
• Adoption of renewable energy in production plants
• Continuous improvement of process efficiency to reduce waste

---

9️⃣ 2. Yantai Dongcheng Pharmaceutical

Headquarters: Yantai, China
Key Offering: Heparin Sodium API, Heparin Calcium API, and specialty anticoagulants

Yantai Dongcheng has a strong foothold in the Asian market, leveraging its extensive distribution network and strategic partnerships with global pharma companies. The firm is expanding its R&D pipeline to include low‑molecular‑weight heparin derivatives.

Sustainability & Growth Initiatives:

• Investment in synthetic heparin alternatives to reduce animal dependence
• Participation in global quality assurance collaborations
• Focus on product safety and traceability through blockchain technology

---

8️⃣ 3. Nanjing King‑Friend Biochemical Pharmaceutical

Headquarters: Nanjing, China
Key Offering: Heparin Sodium API, Heparin Calcium API, and anticoagulant formulation services

King‑Friend Biochemical has a robust manufacturing portfolio, serving both domestic and international markets. The company emphasizes stringent quality control and rapid turnaround times for custom API orders.

Sustainability & Growth Initiatives:

• Adoption of green chemistry principles in API synthesis
• Collaboration with academic institutions for process innovation
• Implementation of ISO 14001 environmental management systems

---

7️⃣ 4. Pfizer

Headquarters: New York, USA
Key Offering: Heparin Sodium API, Heparin Calcium API, and integrated anticoagulant drug development

Pfizer’s global reach and strong R&D capabilities position it as a key player in the heparin API market. The company’s focus on clinical trials and regulatory approvals ensures a steady pipeline of new anticoagulant therapies.

Sustainability & Growth Initiatives:

• Investment in sustainable sourcing of raw materials
• Participation in global health initiatives to improve access to anticoagulants
• Commitment to reducing carbon footprint across manufacturing sites

---

6️⃣ 5. Hebei Changshan Biochemical Pharmaceutical

Headquarters: Hebei, China
Key Offering: Heparin Sodium API, Heparin Calcium API, and custom anticoagulant solutions

Hebei Changshan’s focus on high‑quality API production has earned it a reputation for reliability in the Asian market. The company is expanding into emerging economies with tailored product offerings.

Sustainability & Growth Initiatives:

• Implementation of waste‑to‑energy processes in manufacturing
• Strengthening supply chain resilience through diversified sourcing
• Active participation in global regulatory harmonization efforts

---

5️⃣ 6. Bioibérica

Headquarters: Madrid, Spain
Key Offering: Heparin Sodium API, Heparin Calcium API, and advanced anticoagulant formulations

Bioibérica leverages its European manufacturing footprint to supply high‑purity APIs to pharmaceutical companies across the continent. The firm’s expertise in process scale‑up supports rapid product launches.

Sustainability & Growth Initiatives:

• Commitment to circular economy practices in raw material usage
• Collaboration with EU health agencies for clinical trial support
• Investment in renewable energy for production facilities

---

4️⃣ 7. Qingdao Jiulong Biopharmaceutical

Headquarters: Qingdao, China
Key Offering: Heparin Sodium API, Heparin Calcium API, and specialty anticoagulants

Qingdao Jiulong focuses on both domestic and export markets, offering cost‑effective heparin APIs backed by rigorous quality assurance.

Sustainability & Growth Initiatives:

• Development of animal‑free synthetic heparin alternatives
• Implementation of ISO 9001 quality management systems
• Engagement in community health outreach programs

---

3️⃣ 8. Changzhou Qianhong Biopharma

Headquarters: Changzhou, China
Key Offering: Heparin Sodium API, Heparin Calcium API, and anticoagulant drug development services

Changzhou Qianhong’s integrated manufacturing and R&D capabilities enable it to provide end‑to‑end solutions for pharmaceutical companies seeking heparin APIs.

Sustainability & Growth Initiatives:

• Adoption of green chemistry in API synthesis
• Investment in advanced purification technologies
• Participation in regional health initiatives

---

2️⃣ 9. Dongying Tiandong Pharmaceutical

Headquarters: Dongying, China
Key Offering: Heparin Sodium API, Heparin Calcium API, and anticoagulant formulation expertise

Dongying Tiandong has a strong presence in the Asian market, focusing on high‑quality API production and efficient supply chain logistics.

Sustainability & Growth Initiatives:

• Implementation of energy‑efficient manufacturing processes
• Strengthening raw material traceability systems
• Collaboration with global health organizations for product access

---

1️⃣ 10. Opocrin

Headquarters: Paris, France
Key Offering: Heparin Sodium API, Heparin Calcium API, and anticoagulant drug development

Opocrin combines strong R&D capabilities with a global distribution network, providing high‑quality heparin APIs to pharmaceutical manufacturers worldwide.

Sustainability & Growth Initiatives:

• Adoption of ISO 14001 environmental management systems
• Investment in renewable energy and waste reduction
• Active participation in EU health regulatory initiatives

---

Download FREE Sample Report: Heparin Sodium API and Heparin Calcium API Market – View in Detailed Research Report

Get Full Report Here: Heparin Sodium API and Heparin Calcium API Market – View in Detailed Research Report

🌍 Outlook: The Future of Heparin Sodium API and Heparin Calcium API Market

The heparin API market is poised for significant expansion driven by the increasing prevalence of cardiovascular diseases, rising surgical procedures, and continuous technological advancements in production methods. Global healthcare systems are increasingly adopting low‑molecular‑weight heparins (LMWH) for outpatient therapy, further expanding the market footprint. By 2034, the market is expected to surpass USD 10 billion, reflecting a CAGR of approximately 12% from 2025 to 2034.

📈 Key Trends Shaping the Market:

• Rapid adoption of LMWH and synthetic heparin alternatives across emerging markets
• Growing emphasis on sustainable sourcing and animal welfare compliance
• Integration of digital traceability systems for raw material and product safety
• Strategic partnerships between API manufacturers and global pharma for accelerated product development

The companies listed above are not only leading the heparin API market but are also shaping the future of anticoagulant therapies worldwide.